HLA B7 Antikörper (PE)
-
- Target Alle HLA B7 Antikörper anzeigen
- HLA B7 (HLA Class I B7 Alpha (HLA B7))
-
Reaktivität
- Human, Non-Human Primate
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser HLA B7 Antikörper ist konjugiert mit PE
-
Applikation
- Flow Cytometry (FACS)
- Spezifität
- The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
- Kreuzreaktivität (Details)
- Human, Non-Human Primates
- Aufreinigung
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- Immunogen
- Papain solubilised HLA-A2, B7
- Klon
- BB7-1
- Isotyp
- IgG1
-
-
- Applikationshinweise
- Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 106 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
- Kommentare
-
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Rekonstitution
- No reconstitution is necessary.
- Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
-
Do not freeze.
Avoid prolonged exposure to light. - Lagerung
- 4 °C
- Informationen zur Lagerung
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).
: "Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS." in: Molecular & cellular proteomics : MCP, Vol. 4, Issue 12, pp. 1888-97, (2005) (PubMed).
: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." in: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).
: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).
: "Immunoradiometric assay for the rapid detection of HLA-B27." in: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).
: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).
: "
-
Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).
-
- Target
- HLA B7 (HLA Class I B7 Alpha (HLA B7))
- Andere Bezeichnung
- HLA-B7 (HLA B7 Produkte)
- Synonyme
- AS antikoerper, HLAB antikoerper, SPDA1 antikoerper, major histocompatibility complex, class I, B antikoerper, HLA-B antikoerper
- Hintergrund
- HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.
- Pathways
- Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-